All Updates

All Updates

icon
Filter
Partnerships
DeepCure partners with Leeds Institute to advance AI-driven rheumatoid arthritis treatment
AI Drug Discovery
Aug 19, 2024
This week:
Partnerships
Intuitive AI partner with Moda Center to implement Oscar Sort recycling technology
Waste Recovery & Management Tech
Yesterday
Management news
Funding
Minze Health raises USD 5.3 million in funding for product and market expansion; appoints new VP
Preventive Healthcare
Yesterday
Partnerships
Firefly Aerospace partners with True Anomaly for Space Force rapid-response mission launches
Space Travel and Exploration Tech
Yesterday
Funding
zkPass raises USD 12.5 million in Series A funding
Enterprise Blockchain Solutions
Yesterday
Partnerships
Ontada partners with Microsoft to process unstructured oncology data using Azure AI
Clinical Trial Technology
Yesterday
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
AI Drug Discovery

AI Drug Discovery

Aug 19, 2024

DeepCure partners with Leeds Institute to advance AI-driven rheumatoid arthritis treatment

Partnerships

  • DeepCure, an MIT spinout using AI for drug discovery, has partnered with the Leeds Institute of Rheumatic and Musculoskeletal Medicine to advance its BET inhibitor for rheumatoid arthritis. The terms and financial details of the agreement have not been disclosed.

  • The collaboration will focus on evaluating DC-9476, a selective BRD4 inhibitor developed by DeepCure, using blood samples and joint biopsies from various patient subgroups. The study aims to analyze gene expression patterns and cytokine levels, particularly in patients resistant to current treatments.

  • DC-9476, generated using DeepCure's AI drug discovery platform, offers a potential alternative to existing rheumatoid arthritis (RA) treatments by selectively inhibiting the BD2 domain of BRD4. In preclinical models, it showed better safety and efficacy compared to standard treatments like TNF and JAK inhibitors.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.